Geron Corporation (NASDAQ:GERN) today announced that they have reached an agreements with the Food and Drug Administration to re-initiate clinical trials for spinal cord injury. The company said that they plan to advance clinical development of their human embryonic stem cell (hESC)-based product, GRNOPC1 which will be used for the treatment of spinal cord injuries. The plan is to let Geron Corporation restart the Phase 1 clinical trial of GRNOPC1 in patients who are suffering from complete thoracic spinal cord injury and to support the future expansion of the clinical trial with patients who are suffering from cervical injuries.

Geron Corporation is one of the developers for the first-in-class biopharmaceuticals that is used for the treatment of cancer and chronic degenerative diseases like spinal cord injury, diabetes and heart failure. GRNOPC1 that is being developed by Geron Corporation is made for the treatment of spinal cord injury but Geron is

...

We are initiating coverage of Oxygen Biotherapeutics, Inc. (OXBO) with an ‘Outperform’ rating. Despite what has been a tumultuous past for the company and a abysmal fate for competitors attempting to develop similar products, the potential upside that Oxycyte offers is too significant to ignore.  Does Oxycyte do what management says it does? (Key Efficacy Question) In theory, Oxycyte has the potential to be a wonder drug -- a sort of WD-40 of medicine. Preclinical data suggests that Oxycyte has astounding potential for the treatment of traumatic brain injury (TBI), decompression sickness, carbon monoxide poisoning, sickle cell crisis, organ preservation and as a neuroprotectant in patients with myocardial infarction or stroke. The effects in TBI were clearly evident in the phase I program conducted by Oxygen Bio in 2006. Initial phase II data from STOP-TBI will become available in 2010. However, data from small ...

Oxygen Biotherapeutics now has a clinical development pipeline which includes seven indications for Oxycyte(TM) emulsion. Oxycyte is the Company’s perfluorocarbon (PFC) therapeutic oxygen carrier. The new Oxycyte pipeline includes: Traumatic Brain Injury, Carbon Monoxide Poisoning, Surgical Iatrogenic Air Embolism, Spinal Cord Injury, Organ Preservation, Decompression Sickness, and Sickle Cell Crisis.

The company has also reported that its topical pipeline includes six additional indications in development for the Oxycyte Gel. The first use of the Dermacyte Gel is for a cosmetic line that is now available for pre-orders via the BuyDermacyte.com website, with product shipment expected in about four weeks. Other uses include treatment for Wounds, Burns, Acne, Rosacea, Cell Treatment after Radiation Therapy, and Erectile Dysfunction. Oxygen Biotherapeudics is also working on two additional uses for Oxycyte Compounds, including a ventilation device called VitaVent and a Deep Immersion Fluorocarbon Treatment for severe burns.

Oxygen Biotherapeutics CEO Chris Stern commented on the

...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Thursday October 15, 2009

DrStockPick.com Stock Report!

PWRM, ACOR, AQNM

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro). Power3 expects to complete phase

...

Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

Thursday October 15, 2009

DrStockPick.com Stock Report!

**************************************************************

ACOR, Acorda Therapeutics, Inc.

ACOR is a biotechnology company developing therapies for spinal cord injury, multiple sclerosis and related nervous system disorders.

The U.S. Food and Drug Administration (FDA) Peripheral and Central Nervous System Drugs (PCNSD) Advisory Committee voted 12 to 1 that clinical data on Fampridine-SR 10 mg twice daily demonstrated substantial evidence of effectiveness as a treatment to improve walking in people with multiple sclerosis and voted 10 to 2 (1 abstention) that it is clinically meaningful and can be safe for use.

The current Fampridine-SR Prescription Drug

...

Yesterday, Geron Corp. (GERN) provided an update on its experimental candidate, GRNOPC1, which is currently under clinical hold. On Aug. 18, Geron suffered a setback when the US Food and Drug Administration (FDA) put its Investigational New Drug (IND) application for the product on hold.

Earlier this year, the FDA cleared the company to begin clinical trials of GRNOPC1 for acute spinal cord injury. However, later the agency placed the trial on hold pending a review of new non-clinical animal study data submitted by the company.

Yesterday, Geron announced that the human study is being delayed as some animals treated with the injection developed microscopic spinal cysts in the regenerating injury site. It said that the cysts were non-proliferative, confined to the injury site and had no adverse effect on the animals.

Importantly, the animals did not develop teratomas (a type of tumor) or any other ectopic structure.

...

Sometime during the middle of the year, Genentech (DNA) shareholders are going to get $95 in cash for each share of Genentech stock they own. In total, nearly $47 billion in funds are expected to be returned to biotechnology investors.We've come up with an effective "basket approach" to re-deploy those funds back into the biotech sector -- in search of the next Genentech.Antisense Makes a Lot of SenseFor a little over $13, investors can pick up one share of Isis Pharmaceuticals (ISIS). Isis is the market leader in antisense technology.We've made it no secret in the past -- we are big fans of antisense. We view the drug discovery engine fueled by Isis' antisense technology very similar to the power of Genentech's recombinant DNA and monoclonal antibody technology breakthroughs of the 1980's. Antisense drugs are still in their infancy, ...

Geron Corp (Nasdaq: GERN): Stock of the Day

by Matt Weinschenk and Katharine Schildt

A simple signature from a government official created at least $50 million in wealth Monday. It’s about time… because it seems as though government officials had been doing nothing but destroying wealth lately.

On Monday, President Obama signed an executive order lifting the restrictions on stem cell research. As he did that, stem cell research firm, Geron Corp (Nasdaq: GERN) surged 16% on the news. It’s pulled back today, but that may be a good thing for investors.

For our purposes, any political or religious considerations are set aside. We’re only interested in the business of stem cells.

The executive order is not a complete “about face” on Bush-era policies. In its most general interpretation, it allows the National Institute of Health (NIH) more authority in

...

Geron Corp. (Nasdaq: GERN): Stock of the Day

by Katharine Schildt, Assistant Editor, The Oxford Club

A New Era for Stem Cell Research

Stem cell research has been a controversial subject for quite some time. And it’s been no secret that the Bush administration wasn’t a big fan. But just days after President Obama’s inauguration, a huge breakthrough has already been made in the administrative logjam.

Obama officially relaxed the restrictions on federal funding of stem cell research, which has sent shares of this biopharmaceutical company soaring.

Geron Corp. (Nasdaq: GERN), based in the United States, is the premiere developer of biopharmaceuticals for the treatment of certain cancers, as well as degenerative diseases such as spinal cord injury and diabetes.

Already a global leader in the development of embryonic stem cell-based therapies, the U.S. Food and Drug Administration (FDA) has now approved Geron to start the first

...

History was made today as Geron Corp. announced that the U.S. Food and Drug Administration (FDA) has granted clearance of the company’s Investigational New Drug (IND) application for the clinical trial of GRNOPC1 in patients with acute spinal cord injury. This unprecedented clearance enables the company to move forward with the world’s first study of a human embryonic stem cell (hESC)-based therapy in man.

“The FDA’s clearance of our GRNOPC1 IND is one of Geron’s most significant accomplishments to date,” stated Thomas B. Okarma, Ph.D., M.D., Geron’s president and CEO. “This marks the beginning of what is potentially a new chapter in medical therapeutics – one that reaches beyond pills to a new level of healing: the restoration of organ and tissue function achieved by the injection of healthy replacement cells. The ultimate goal for the use of GRNOPC1 is to achieve restoration of spinal cord function by the injection of

...